BLENREP▼ (Belantamab mafodotin) logo

Product menu

BLENREP is indicated in adults for the treatment of multiple myeloma:1

  • In combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and
  • In combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide
Explore BLENREP dosing and administration

Learn more about a BLENREP backbone that offers you the opportunity to tailor treatment at 2L to meet your eligible adult patients’ needs

Explore BLENREP dosage reductions and delays

BLENREP (belantamab mafodotin) offers a minimum infusion time of 30 minutes and dose modifications to help manage side effects.1

Image showing patient IV and eye icons

Can be given in an outpatient setting.2

Image showing patient IV and eye icons

No SPC-specified post-infusion monitoring window beyond your normal clinical practice.*1

BLENREP can be delayed, reduced or discontinued as part of a strategy to manage side effects.†2,3 Pre-treatment eye care appointments help to monitor for any eye-related side effects.1 Please see the SPC for the recommended monitoring schedule.

*Monitor patients for infusion-related reactions. For Grade 2 or 3 reactions, interrupt the infusion and provide supportive treatment. Once symptoms resolve to Grade 1 or better, resume BLENREP at a lower infusion rate. Administer premedication for all subsequent infusions. Permanently discontinue BLENREP for life-threatening infusion-related reactions and provide appropriate emergency care.
†Discontinuation rate of any component of therapy in the DREAMM-7 study was 31%, and in the DREAMM-8 study it was 15%.

Explore the Managing side effects page

A BLENREP backbone offers you the opportunity to tailor treatment at 2L to meet your eligible adult patients' needs1,4,5

It is useful for you to know how your patients’ dosing may be modified to help manage side effects with each BLENREP combination.

Once a dose of BLENREP has been reduced, it should not be re-escalated.1

BLENREP dosing in combination with bortezomib + dexamethasone (Vd)

Figure showing the dosing schedule for BLENREP in combination with Vd Figure showing the dosing schedule for BLENREP in combination with Vd

Adapted from BLENREP Summary of Product Characteristics.

Please refer to the SPC for full dosing guidance before prescribing.

View full figure

*Please see SPC for dose adjustments in thrombocytopenia with or without active bleeding.1

Grade 4 adverse events may require permanent discontinuation of BLENREP.

For full breakdown of dose adjustments, including when to permanently discontinue, visit the managing side effects page

BLENREP + Vd treatment schedule

Figure showing the treatment schedule for BLENREP in combination with Vd Figure showing the treatment schedule for BLENREP in combination with Vd

Treatment schedule for the ninth cycle onwards
Patients will receive BLENREP as monotherapy.

NA

BLENREP

NA

Bortezomib

NA

Dexamethasone

Figure showing the treatment schedule for BLENREP in combination with Vd Figure showing the treatment schedule for BLENREP in combination with Vd

Adapted from BLENREP Summary of Product Characteristics.

View full figure

Your patient’s BLENREP dose and schedule may be modified to help manage side effects, including those that are eye-related.1

Explore more information on managing side effects

Explore resources to help you to support your eligible adult patients on BLENREP

BLENREP dosing in combination with pomalidomide + dexamethasone (Pd)

Figure showing the dosing schedule for BLENREP in combination with Pd Figure showing the dosing schedule for BLENREP in combination with Pd

Adapted from BLENREP Summary of Product Characteristics.

Please refer to the SPC for full dosing guidance before prescribing.

View full figure

*Please see SPC for dose adjustments in thrombocytopenia with or without active bleeding.1 †For grade 4 ERSEs, BLENREP can be restarted at a reduced dose of 1.4 mg/kg Q8W.

Grade 4 adverse events may require permanent discontinuation of BLENREP.

For full breakdown of dose adjustments, including when to permanently discontinue, visit the managing side effects page

BLENREP + Pd treatment schedule

Figure showing the treatment schedule for BLENREP in combination with Pd Figure showing the treatment schedule for BLENREP in combination with Pd

BLENREP starting dose is 2.5 mg/kg given ONCE.1
From cycle 2 onwards the dose is 1.9 mg/kg Q4W.1

NA

BLENREP

NA

Pomalidomide

NA

Dexamethasone

Adapted from BLENREP Summary of Product Characteristics.

View full figure

Your patient’s BLENREP dose and schedule may be modified to help manage side effects, including those that are eye related.1

Explore more information on managing side effects

Explore resources to help you to support your eligible adult patients on BLENREP

BLENREP dosage reductions and delays

In the DREAMM-7 and DREAMM-8 clinical trials, BLENREP dosage reductions and delays were common, and efficacy was generally sustained.6,7

In DREAMM-7, the primary endpoint was median progression-free survival (mPFS). BLENREP + Vd demonstrated superiority vs DVd with a mPFS of 36.6 months (95% CI: 28.4–NR) vs 13.4 months (95% CI: 11.1–17.5). Hazard ratio for disease progression or death was 0.41 (95% CI: 0.31–0.53) (P<0.00001).6

In DREAMM-8, the primary endpoint was also mPFS. BLENREP + Pd delayed disease progression or death vs PVd with median PFS not reached (95% CI: 20.1–NR) vs 12.7 months (95% CI: 9.1–18.5). Hazard ratio for disease progression or death was 0.52 (95% CI: 0.37–0.73) (P<0.001).7

Icon showing an IV bag and clock

BLENREP dosing in combination with Pd or Vd

• 75% and 61% of patients experienced dose reductions of any component therapy in DREAMM-7 and DREAMM-8, respectively.

• 94% and 91% of patients experienced dose delays in DREAMM-7 and DREAMM-8, respectively.

• Discontinuation rates were 31% (75/242) in DREAMM-7 and 15% (22/150) in DREAMM-8.6,7

Icon showing an eye

Over time, the interval between doses increased to manage eye-related events1

• The median time between doses after 12 months was 9.5 weeks in DREAMM-7 and 14.1 weeks in DREAMM-8.

Icon showing an IV bag and a triangle

Efficacy was maintained with dose delays of ≥12 weeks*2,3,6

• Among patients with extended dose delays (≥12 weeks) in DREAMM-7 and DREAMM-8, median PFS remained consistent with the ITT population.† This is a post-hoc analysis conducted in patients with ≥6 months of treatment. No formal statistical testing was completed.

DREAMM-7:
ITT population (n=243) [36.6 (28.4–NR)]
Patient with ≥1 dose delay of ≥12 weeks (n=126) [36.6 (33.2–NR)].

DREAMM-8:
ITT population (n=155) [NR (20.6–NR)]
Patient with ≥1 dose delay of ≥12 weeks (n=93) [NR (NR–NR)].

In line with SPC recommendations, BLENREP dosing can be delayed, reduced or discontinued as part of a strategy to manage side effects.1

*In 126/242 patients with ≥1 dose delay of ≥12 weeks, median PFS was 36.6 (95% CI: 33.2–NR).
†Only patients receiving ≥6 months of treatment were included in the analysis to exclude early discontinuations (e.g. rapid progressive disease).

In DREAMM-7, the most frequently reported non-eye related side effects (≥20%) were thrombocytopenia (87%), diarrhoea (32%), and upper respiratory tract infections (URTIs) (20%), and in DREAMM-8, these were neutropenia (63%), thrombocytopenia (55%) fatigue (27%), URTIs (27%), pneumonia (24%), anaemia (23%), and diarrhoea (23%).1

The most frequently reported eye-related side effects in DREAMM-7 (≥20%) were reduced visual acuity (89%), corneal examination findings (86%), blurred vision (66%), dry eye (51%), photophobia (47%), foreign body sensation in eyes (44%), eye irritation (43%) and eye pain (32%).1

The most frequently reported eye-related side effects (≥20%) in DREAMM-8 included reduced visual acuity (91%), corneal examination findings (87%), blurred vision (79%), foreign body sensation in eyes (61%), dry eye (61%), eye irritation (50%), photophobia (44%) and eye pain (33%).1

Learn how to manage side effects with dose reduction guidance

Abbreviations

2L, second line; CI, confidence interval; DVd, daratumumab, bortezomib, dexamethasone; ITT, intention-to-treat; mPFS, median progression-free survival; NR, not reached; Pd, pomalidomide, dexamethasone; PFS, progression-free survival; Q3W, once every 3 weeks; Q4W, once every 4 weeks; Q8W, once every 8 weeks; SPC, Summary of Product Characteristics; URTI, upper respiratory tract infection; Vd, bortezomib, dexamethasone.

References

  1. BLENREP. Summary of Product Characteristics. GlaxoSmithKline; 2025.
  2. Hungria, V, Robak P, Hus M, et al. Characterization and management of ocular events in patients treated with belantamab mafodotin plus bortezomib and dexamethasone in the DREAMM-7 Study. Presented at 2024 IMS Annual Meeting. 28-29 September. Rio de Janeiro, Brazil.
  3. Quach H, Dimopoulos MA, Beksac M, et al. Characterization and management of ocular events in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone in the DREAMM-8 study. Presented at 2024 IMS Annual Meeting. 28-29 September. Rio de Janeiro, Brazil.
  4. Yang Y, Zhao B, Lan H, et al. Bortezomib-induced peripheral neuropathy: Clinical features, molecular basis, and therapeutic approach. Critical Reviews in Oncology/Hematology 2024;197:104353.
  5. Dimopoulos MA, Leleu X, Moreau P, et al. Expert panel consensus statement on the optimal use of Pomalidomide in relapsed and refractory multiple myeloma. Leukemia 2014;28:1573-1585.
  6. Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024 Aug 1;391(5):393–407.
  7. Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med. 2024 Aug 1;391(5):408–21.

▼This product is subject to additional monitoring. Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (available on the Apple App Store or Google Play Store). Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or UKSafety@GSK.com.

October 2025 | PM-GB-BLM-WCNT-250016 (V1.0)